At a glance
ClinicalIndex Comparison RecordN/ACompleted· 61 enrolled
Drug / intervention
Niagen +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment in Aging
In Brief
A clinical study evaluating Niagen and Placebo Comparator for Cognition Disorders in Old Age and 2 related conditions. Completed, enrolled 61 participants across 1 site.
Detailed Summary
In this research study we want to learn more about whether taking Niagen, a daily supplement containing a form of Vitamin B3, will improve cognitive function, mood, and daily activity in people with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartOct 2020
Primary CompletionSep 2022
TodayJul 2026
First PostedSep 4, 2019
Enrollment StartOct 30, 2020
Primary CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.8 years ago
Interventions
Niagendietary
Nicotinamide Riboside
Placebo Comparatordietary
Placebo